大黄牡丹汤治疗晚期转移性结直肠癌的疗效

摘要/Abstract

摘要： 目的探讨大黄牡丹汤治疗晚期转移性结直肠癌的疗效及对血清肿瘤标志物水平的影响。方法选取扬州市中医院2018年1月~2020年12月收治的晚期转移性结直肠癌患者60例作为研究对象,根据随机数表法把患者分为试验组与对照组,各30例,对照组给予常规化疗,试验组在对照组的基础上给予大黄牡丹汤治疗。观察试验组与对照组的疗效,治疗期间两组患者出现的不良反应情况,治疗前后检测血清癌胚抗原（CEA）与糖链抗原（CA）242含量,治疗前后两组患者卡氏评分（KPS）,治疗后随访1年,记录患者的中位生存时间与中位无进展生存期。结果治疗后总有效率比较,试验组高于对照组（P<0.05）。试验组治疗期间的呕吐恶心、贫血、白细胞减少、中性粒细胞减少等不良反应发生率都低于对照组（P<0.05）。两组治疗后的KPS评分高于治疗前,且试验组高于对照组（P<0.05）。治疗后,两组患者血清CEA与CA242水平均低于治疗前（P<0.05）,试验组低于对照组（P<0.05）。所有患者随访1年,试验组的中位生存时间与中位无进展生存期都长于对照组（P<0.05）。结论大黄牡丹汤治疗晚期转移性结直肠癌能提高治疗疗效,减少不良反应的发生,抑制血清CEA与CA242的释放,改善患者的生存质量,延长患者的生存时间。

关键词: 大黄牡丹汤, 晚期转移性结直肠癌, 不良反应, 肿瘤标志物, 生存质量

Abstract: Objective To investigate the curative effect of Dahuang Mudan Decoction in the treatment of advanced metastatic colorectal cancer and its influence on the level of serum tumor markers. Methods A total of 60 patients with advanced metastatic colorectal cancer who were admitted to Yangzhou Hospital of Traditional Chinese Medicine from January 2018 to December 2020 were selected as the subjects. All the cases were divided into the experimental group and the control group with 30 cases each groups accorded to the 1:1 random envelope drawing principle, the control group group were given conventional chemotherapy, and the experimental group were given Dahuang Mudan Decoction on the basis of the conventional chemotherapy group's treatment. The curative effects of the two groups were observed, the toxic and side effects of the patients were observed during the treatment, the serum carcinoembryonic antigen (CEA) and carbohydrate antigen (CA) 242 contents were detected before and after treatment, and the patients were evaluated for Karnofsky score before and after treatment (karnofsky performance status, KPS), followed up for 1 year after treatment, and recorded the survival of patients. Results After treatment, the total effective rate of the experimental group were higher than the control group (P<0.05). During treatment, the incidence of nausea and vomiting, anemia,leukopenia, and neutropenia in the texperiental group were lower than those in the control group (P<0.05). The KPS scores of the experimental group and the control group after treatment were higher than those before treatment, and the experimental group was higher than the control group (P<0.05). Serum CEA and CA242 levels after treatment in the two groups were lower than before treatment (P<0.05), and the experimental group were lower than the control group (P<0.05). All patients were followed up for 1 year, and the median survival time and median progression-free survival of the experimental group were longer than those of the control group (P<0.05). Conclusion Dahuang Mudan Decoction in the treatment of advanced metastatic colorectal cancer can improve the therapeutic effect, reduce the occurrence of toxic and side effects, inhibit the release of serum CEA and CA242, improve the quality of life of patients, and prolong the survival time of patients.

Key words: Dahuang Mudan Decoction, advanced metastatic colorectal cancer, adverse reaction, tumor markers, quality of life

中图分类号:

R735.35

王庆颖. 大黄牡丹汤治疗晚期转移性结直肠癌的疗效[J]. 中华养生保健, 2022, 40(21): 13-16.

WANG Qing-ying. Efficacy of Dahuang Mudan Decoction in the Treatment of Advanced Metastatic Colorectal Cancer[J]. ZHONGHUA YANGSHENG BAOJIAN, 2022, 40(21): 13-16.

参考文献

[1] 张福杰,于登峰,王艺.CapeOX和SOX化疗方案治疗晚期结直肠癌的疗效观察[J].中国肿瘤临床与康复,2021,28(2):152-156.
[2] 林嘉敏,吴夏慧,罗毅.结直肠癌的炎癌转化研究进展[J].中国肿瘤临床与康复,2021,28(3):378-381.
[3] 陈叶青,李晓琳,陈子睿,等.基于数据挖掘的结直肠癌中医证型与中药应用规律研究[J].中国中医基础医学杂志,2022,28(3):412-416.
[4] 王玉,江滨,方明治,等.加味当归补血汤对结直肠癌术后化疗患者免疫功能和骨髓抑制的干预作用研究[J].江苏中医药,2018,50(12):33-35.
[5] 伍谨林,杨柱,龙奉玺,等.基于网络药理学研究白头翁汤治疗结直肠癌的作用机制[J].中成药,2021,43(11):3206-3215.
[6] 汪耔璇,李烜.补中益气汤联合化疗治疗晚期结直肠癌临床研究[J].陕西中医,2020,41(10):1414-1417.
[7] 蔡明明,杨会举.益气通腑汤对保护性肠造口术后患者康复及营养状况的影响[J].中医学报,2021,36(5):1093-1096.
[8] 周世勇,艾飞,高波,等.自拟翁苓参芍汤加减五倍子治疗老年结直肠癌术后脾虚湿热瘀毒型泄泻的临床效果[J].中国老年学杂志,2021, 41(9):1824-1827.
[9] 刘首记,言纲,聂青.扶正抑瘤汤联合化疗对结直肠癌患者T淋巴细胞水平及转归的影响[J].世界中西医结合杂志,2021,16(6):1123-1127.
[10] 孟启明,卢言琪,陈玉英,等.健脾养胃汤联合参苓全营养制剂在结直肠癌癌性营养不良患者的应用[J].世界中医药,2021,16(8):1284-1288.
[11] 中华医学会外科学分会胃肠外科学组,中华医学会外科学分会结直肠肛门外科学组,中国抗癌协会大肠癌专业委员会,等.结直肠癌肝转移诊断和综合治疗指南(V2016)[J].中华胃肠外科杂志,2016, 19(7):721-730.
[12] 钟育波,罗兵,彭树灵,等.益气健脾汤联合腹腔热灌注化疗治疗结直肠癌腹膜转移的临床研究[J].山西医药杂志,2022,51(1):3-8.
[13] 唐末,杨宇飞,宋卓,等.基于网络药理学探讨四君子汤治疗结直肠癌靶点及通路研究[J].国际中医中药杂志,2022,44(2):206-211.
[14] 钟灼,高飞,赵永心,等.125I放射性粒子植入术后卡培他滨单药化疗联合二陈汤治疗晚期结直肠癌疗效分析[J].中国肿瘤临床与康复,2021,28(3):257-262.
[15] 张旭,赵磊,林峰,等.中西医结合疗法改善低位直肠癌完全经肛门括约肌间切除术后患者肛门功能的临床研究[J].中国中西医结合外科杂志,2021,27(2):268-271.
[16] 熊礼凤,孙杭.白头翁汤加味联合化疗治疗湿热蕴结型晚期结直肠癌临床观察[J].浙江中医杂志,2021,56(7):509.
[17] Van Den Ende T, Van Den Boorn H G, Hoonhout N M, et al. Priming the tumor immune microenvironment with chemo(radio)therapy: A systematic review across tumor types[J]. Biochim Biophys Acta Rev Cancer, 2020,1874(1):183086.
[18] Vermani L, Kumar R, Senthil Kumar N.GAPDH and PUM1: Optimal Housekeeping Genes for Quantitative Polymerase Chain Reaction-Based Analysis of Cancer Stem Cells and Epithelial-Mesenchymal Transition Gene Expression in Rectal Tumors[J]. Cureus,2020,12(12):e12020.
[19] 唐晓龙,金庆江,王瑞平,等.基于反向分子对接和网络药理学预测木兰花碱抗肿瘤的潜在作用机制[J].世界科学技术-中医药现代化,2021,23(4):1108-1118.
[20] 杨忠明,曾瑞,李五生,等.贞芪六君抑癌汤配合mFOLFOX6联合贝伐珠单抗治疗晚期转移性结直肠癌临床疗效分析[J].中医肿瘤学杂志,2021,3(4):22-25,21.